In the BioHarmony Drug Report Database

"Preview" Icon

Elagolix

Orilissa (elagolix) is a small molecule pharmaceutical. Elagolix was first approved as Orilissa on 2018-07-23. It is used to treat abdominal pain in the USA. The pharmaceutical is active against gonadotropin-releasing hormone receptor. Orilissa’s patents are valid until 2036-09-01 (FDA).

 

Trade Name

 

Orilissa
 

Common Name

 

elagolix
 

ChEMBL ID

 

CHEMBL1208155
 

Indication

 

abdominal pain
 

Drug Class

 

Gnrh receptor antagonists (nonpeptide)

Image (chem structure or protein)

Elagolix structure rendering